Vectra DA Testing Now Available in All 50 States

VBCR - June 2013, Volume 2, No 3 - Personalized Medicine in Rheumatology

The Vectra DA test is a multibiomarker blood test that measures disease activity in patients with rheumatoid arthritis (RA)  by integrating 12 key proteins that are consistently associated with the biology of RA into a single, objective, and quantitative score to help rheumatologists make more informed treatment decisions.

In April 2013, the New York State Department of Health issued a permit to Crescendo Bioscience, a molecular diagnostic company, to provide laboratory services to physicians in New York. With this clearance, Vectra DA is now available in all 50 states.

“This is welcome news for the more than 400 rheumatologists in New York,” said Max Hamburger, MD, President of the New York State Rheumatology Society. “To effectively treat our patients, we need to have the most advanced technology available that can help bring us closer to achieving treatment success. Vectra DA is a valuable tool that can enhance the assessment of RA disease activity to aid rheumatologists in achieving better management of the disease,” Dr Hamburger emphasized.

Vectra DA test results are reported back within 7 to 10 days of receipt of the sample. Physicians can either receive the test results via standard mail, by fax, or through the private web portal, Vectra View.

“This is an exciting step in our continuing efforts to bring Vectra DA to more RA patients to help improve their care,” William A. Hagstrom, President and Chief Executive Offi­cer of Crescendo Bioscience, stated. “Since Vectra DA’s introduction in late 2010, more than 20% of the rheumatologists in the United States have successfully used it to evaluate more than 40,000 patients’ disease. We look forward to working with rheumatologists in New York and across the United States to increase access to the important information that Vectra DA provides,” he said.

“New York’s Clinical Laboratory Evaluation Program clearance is further evidence of the quality of the testing performed by Crescendo. Vectra DA can offer insight on disease activity that may not be captured by current standards of RA measurement,” said Stephen Paget, MD, FACP, FACR, Physician-in-Chief Emeritus of the Division of Rheumatology at the Hospital for Special Surgery, New York, NY. “Vectra DA brings a deep understanding of the underlying disease biology that can be utilized in the clinic and in clinical trials as we continue to develop potential new treatments for RA patients.”

Related Items
MBDA May Predict Post-TNFi Flares in Patients with Rheumatoid Arthritis
Rosemary Frei, MSc
VBCR - December 2015, Volume 4, No 6 published on December 15, 2015 in Personalized Medicine in Rheumatology
RA Disease Marker Proving to Be Versatile
Rosemary Frei, MSc
VBCR - December 2015, Volume 4, No 6 published on December 15, 2015 in Personalized Medicine in Rheumatology
MBDA May Predict RA Relapses During DMARD Tapering
Rosemary Frei, MSc
VBCR - December 2015, Volume 4, No 6 published on December 15, 2015 in Personalized Medicine in Rheumatology
Autoantibodies in Patients with RA Could Lead to More Precise Diagnosis, Therapy
E. K. Charles
VBCR - October 2014, Volume 3, No 5 published on October 30, 2014 in Personalized Medicine in Rheumatology
Advances in Genotyping Pinpoints to Genetic Determinant
Phoebe Starr
VBCR - August 2014, Volume 3, No 4 published on September 12, 2014 in Personalized Medicine in Rheumatology
Gene Expression Profiling Shows Potential in Personalized Medicine for RA
E. K. Charles
VBCR - June 2014, Volume 3, No 3 published on July 1, 2014 in Personalized Medicine in Rheumatology
Novel Plasma Cell Signature May Be Useful in a Range of Rheumatic Disorders
Alice Goodman
VBCR - April 2014, Volume 3, No 2 published on April 23, 2014 in Personalized Medicine in Rheumatology
New RA Susceptibility Locus Identified
Alice Goodman
VBCR - April 2014, Volume 3, No 2 published on April 23, 2014 in Personalized Medicine in Rheumatology
Future Therapies May Come from Modulation of Cell Signaling in Rheumatic Disease
Phoebe Starr
VBCR - February 2014, Volume 3, No 1 published on February 21, 2014 in Personalized Medicine in Rheumatology
Osteoarthritis Biomarker Field Fraught with Challenges
VBCR - December 2013, Volume 2, No 6 published on December 30, 2013 in Personalized Medicine in Rheumatology
Last modified: May 21, 2015
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology